TY - JOUR
T1 - Differences between squamous cell carcinoma and adenocarcinoma of the lung
T2 - Are adenocarcinoma and squamous cell carcinoma prognostically equal?
AU - Kawase, Akikazu
AU - Yoshida, Junji
AU - Ishii, Genichiro
AU - Nakao, Masayuki
AU - Aokage, Keiju
AU - Hishida, Tomoyuki
AU - Nishimura, Mitsuyo
AU - Nagai, Kanji
N1 - Funding Information:
The work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan.
PY - 2012/3
Y1 - 2012/3
N2 - Objective: We analyzed pulmonary squamous cell carcinoma and adenocarcinoma patient survival in our single institution database, to evaluate the relationship of histologic analysis to survival and tumor aggressiveness. Methods: We reviewed 1856 consecutive patients with surgically resected pulmonary squamous cell carcinoma or adenocarcinoma regarding their clinicopathologic characteristics, overall survival and recurrence-free proportion. Results: In squamous cell carcinoma patients, there were more elderly male smokers and more patients with T2-4 tumors, moderately/poorly differentiated tumors, lymph node metastasis or vascular invasion than in adenocarcinoma patients. In all patients and in pN0 patients, patients with squamous cell carcinoma showed significantly poorer overall survival than those with adenocarcinoma, but there were no statistically significant differences in the recurrence-free proportion between the two histologic types. There were statistically significantly more lung cancer-specific deaths in patients with adenocarcinoma than in patients with squamous cell carcinoma (P= 0.001). Conclusions: There were no differences in the development of recurrence between squamous cell carcinoma and adenocarcinoma of the lung, but considerable differences in overall survival were observed between the two histologic types. According to the stage grouping strategy of the TNM Classification for Lung and Pleural Tumours, these two histologic types need to be staged differently. This survival difference, however, may reflect the difference in patient background rather than in biologic aggressiveness between the two histologic types.
AB - Objective: We analyzed pulmonary squamous cell carcinoma and adenocarcinoma patient survival in our single institution database, to evaluate the relationship of histologic analysis to survival and tumor aggressiveness. Methods: We reviewed 1856 consecutive patients with surgically resected pulmonary squamous cell carcinoma or adenocarcinoma regarding their clinicopathologic characteristics, overall survival and recurrence-free proportion. Results: In squamous cell carcinoma patients, there were more elderly male smokers and more patients with T2-4 tumors, moderately/poorly differentiated tumors, lymph node metastasis or vascular invasion than in adenocarcinoma patients. In all patients and in pN0 patients, patients with squamous cell carcinoma showed significantly poorer overall survival than those with adenocarcinoma, but there were no statistically significant differences in the recurrence-free proportion between the two histologic types. There were statistically significantly more lung cancer-specific deaths in patients with adenocarcinoma than in patients with squamous cell carcinoma (P= 0.001). Conclusions: There were no differences in the development of recurrence between squamous cell carcinoma and adenocarcinoma of the lung, but considerable differences in overall survival were observed between the two histologic types. According to the stage grouping strategy of the TNM Classification for Lung and Pleural Tumours, these two histologic types need to be staged differently. This survival difference, however, may reflect the difference in patient background rather than in biologic aggressiveness between the two histologic types.
KW - Adenocarcinoma
KW - Histologic type
KW - Prognosis
KW - Squamous cell carcinoma
KW - TNM classification
UR - http://www.scopus.com/inward/record.url?scp=84857978086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857978086&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyr188
DO - 10.1093/jjco/hyr188
M3 - Article
C2 - 22210923
AN - SCOPUS:84857978086
SN - 0368-2811
VL - 42
SP - 189
EP - 195
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 3
M1 - hyr188
ER -